English 中文
English
 
 

About Decheng Capital

Decheng Capital is a leading investment firm that provides capital and strategic support to early stage life science companies with revolutionary technologies and growth stage healthcare companies with strong market presence. Located in Shanghai and Silicon Valley, we are a group of dedicated professionals with complementary expertise who have outstanding track records of building highly successful companies both in China and U.S. Founded in 2012, Decheng continues to capitalize on a historic opportunity in the rapid growth of China’s healthcare industry as well as breakthroughs in life science research worldwide. With over $440 million in capital under management and support from some of the most prestigious LPs in the world, Decheng is poised to deliver superior returns for our investors and create value for our entrepreneur partners.

 

News

November 14, 2016
Dan Zabrowski Joins Decheng Capital as Venture Partner

October 25, 2016
First Scientist to Discover Fetal DNA in Plasma Co-Founds Cirina for Early Detection of Deadly Diseases

September 28, 2016
ReadCoor Announces Launch from Wyss Institute Following Completion of Series A Financing Round

September 27, 2016
SentreHEART Announces Closing of $35M Funding Round for aMAZE Trial

June 1, 2016
AccuraGen Raises $40M in Series B Financing

March 29, 2016
Dennis Lo, Co-founder of Cirina, featured on CNN

August 25, 2015
Becton Dickinson Acquires Single-Cell Genomics Startup Cellular Research

August 13, 2015
Roche Acquires GeneWEAVE for up to $425 Million to Strengthen Offerings in Microbiology Diagnostics

May 26, 2015
3SBio Attracts $712 million Hong Kong IPO

Copyright © 2011 Decheng Capital LLC. All Rights Reserved.